Dylan H. Roby, PhD, is Associate Chair and Associate Professor in the Department of Health Policy and Management at the University of Maryland School of Public Health. His research focus is on Medicaid, community health centers, safety net hospitals, delivery system change, and the Affordable Care Act's implications for insurance markets, system redesign and access to care. He teaches courses on health politics and policy in the MHA, MPH and PhD programs in the department. Roby collaborates with colleagues at UC Berkeley and UCLA on the California Simulation of Insurance Markets (CalSIM) microsimulation model (www.calsim.org), which he helped develop over the past decade, and is a member of the cost analysis team for the California Health Benefit Review Program (www.chbrp.org). Although his primary academic appointment is in the University of Maryland's School of Public Health, he is a faculty associate with the UCLA Center for Health Policy Research and an adjunct associate professor of health policy and management at UCLA. Dr. Roby has been interviewed and quoted by various media outlets, including the Los Angeles Times, New York Times, CNN, Fox News, Al Jazeera America, Cosmopolitan, CBS radio, and NPR-affiliates including KPCC, WAMU, Wisconsin Public Radio, and KQED.

As the former director (2012-2014) of the Health Economics and Evaluation Research Program at the UCLA Center for Health Policy Research, Dr. Roby helped developed the Center's capacity for analysis of Medicaid claims data, Medicaid waiver evaluation, and conducting confidential data analyses and surveys. He served as the associate director of the UCLA MPH Program in Health Policy and Management from 2010-2012. Prior to becoming the director of Health Economics and Evaluation Research, he was a senior researcher at the Center from 2003 to 2011. Prior to that, Dr. Roby worked for four years as a senior research associate at The George Washington University Center for Health Services Research and Policy. He worked on safety net issues, including data analysis and research on community health centers and public hospitals. During his first stint in Washington, DC, he also worked for the National Association of Community Health Centers, the National Governors' Association's Center for Best Practices, and the Progressive Policy Institute. Prior to that, he was a research assistant at the UCLA Center for Health Policy Research.

Roby graduated from UCLA with a bachelor's degree in geography and a minor in public policy. He earned his doctoral degree in public policy from The George Washington University.

Michael is global co-head of the Office of Government Affairs. He joined Goldman Sachs as a managing director in 2009.

Prior to joining the firm, Michael was executive vice president for Global Advocacy at the Securities Industry and Financial Markets Association (SIFMA), where he was responsible for global legal, governmental, and legislative affairs and advocacy initiatives. Previously, he was Deputy Staff Director of the US House Financial Services Committee and he also had joint responsibility for Committee policy related to the banking, securities and insurance industries.

Earlier in his career, Michael worked at Mercantile Bankshares Corporation, where he held several senior positions, including executive vice president and chief administrative officer. Before joining Mercantile, he held the position of Senior Minority Counsel with the House Financial Services Committee. Michael has also held positions at JPMorgan Chase & Co. and was an associate at Davis Polk & Wardwell with the financial institutions practice.

Michael earned a BA from Notre Dame and a JD from Notre Dame Law School.

Sharyl Nass, Ph.D. is Director of the Board on Health Care Services and Director of the National Cancer Policy Forum at the National Academies of Sciences, Engineering, and Medicine. The Board’s activities pertain to the organization, financing, effectiveness, workforce, and delivery of health care. The Cancer Forum examines policy issues pertaining to the entire continuum of cancer research and care. For more than 15 years, Dr. Nass has worked on a broad range of health policy topics that includes the quality and safety of care, clinical trials, oversight of health research, developing biomarkers and omics-based tests to guide patient care, technologies and quality standards for breast imaging, strategies for large-scale biomedical science, and contraceptive research and development. With a Ph.D. in cell and tumor biology from Georgetown University and postdoctoral training at the Johns Hopkins University School of Medicine, she has published papers on the cell and molecular biology of breast cancer. She also holds a BS in genetics and an MS in Endocrinology/Reproductive Physiology, both from the University of Wisconsin-Madison. In addition, she studied developmental genetics and molecular biology at the Max Planck Institute in Germany under a fellowship from the Heinrich Hertz-Stiftung Foundation. She was the 2007 recipient of the Cecil Award for Excellence in Health Policy Research, the 2010 recipient of a Distinguished Service Award from the National Academies, and the 2012 recipient of the Institute of Medicine staff team achievement award (as the team leader).

Deborah Kamin, RN, PhD, joined ASCO in 1998, leading the Society’s work on a wide range of issues of concern to oncology professionals in all practice settings. Prior to joining ASCO she directed health policy and benefit design for the Department of Defense civilian health insurance program, TRICARE, which covers more than 9 million beneficiaries worldwide. Dr. Kamin earned a bachelor’s degree in nursing at the Medical College of Georgia, a master’s degree in management science at the Naval Postgraduate School, and a PhD in health policy at the George Washington University.

Lovell A. Jones, PhD, a member of the Research Faculty in the College of Science & Engineering at Texas A&M University in Corpus Christi previously held the post professor in the Department of Health Disparities Research and Founding Director of the joint UT MD Anderson Cancer Center/University of Houston Dorothy I. Height Center for Health Equity & Evaluation Research. He is now Professor Emeritus in the Department of Health Disparities Research at the University of Texas M.D. Anderson Cancer Center as well as the University of Texas Graduate School of Biomedical Sciences, one of the few individuals to hold such a position at two UT System institutions. He continues to serve on a number of advisory groups and boards that focus on addressing health equity. He has more than 35 years of experience in addressing minority health and the health of the underserved. As a scientist, he has also done extensive research into the relationship between hormones, diet and endocrine responsive tumors and has presented his work both nationally and internationally. He has edited one of the few comprehensive textbooks on this subject: Minorities & Cancer. He has chaired or co-chaired numerous major events regarding the underserved and cancers, including the 1st National African Cancer Education meeting in Abuja, Nigeria. He is co-author of the congressional resolution designating the third full week in April as "National Minority Cancer Awareness Week." For his work, the NIH/National Center on Minority Health and Health Disparities was awarded him its Director’s Award for Excellence in Health Disparities. He has also received the Ruth Kirschstein Diversity in Science Award and was selected as one of the top African American Scientist in America by the National Science Foundation “The History Makers.” In January 2000, he was named the first director of the congressionally mandated Center for Research on Minority Health (CRMH), a multidisciplinary center which aims to a) foster research that addresses the causes of health disparities and translates scientific results back to the communities affected by those disparities; b) encourage minority students to pursue careers in the biomedical sciences; and c) increase recruitment and retention of minority and medically underserved populations into clinical trials.

Diana D. Jeffery, PhD, is a health psychologist with more than 30 years of health research experience. She is a healthcare research analyst at the Defense Health Agency, Clinical Support Division, Department of Defense. Her research focuses on health care costs, utilization and policies related to cancer care, the impact of chronic comorbid conditions among cancer survivors, substance use, and patient-outcome measures. She currently serves on the Board of the Scientific Network for Female Sexual Health and Cancer and is an advisor to the CSC Cancer Policy Institute.

Fauzea Hussain currently serves as the Vice President, Public Policy for McKesson. In this role, Fauzea works across the enterprise to ensure McKesson’s public policy strategy meets the diverse needs of McKesson’s comprehensive suite of solutions across the care continuum, while meeting the company’s mission of creating a sustainable healthcare environment that drives better health for all patients. She works across the business on issues impacting distributors and wholesalers, community providers, health systems, pharmacies, and most importantly patients. Fauzea is a seasoned policy expert with more than 20 years of experience in assessing the impact of state and federal policy and market changes on patient access, provider reimbursement and the life sciences industries. Prior to joining McKesson, Fauzea led Avalere’s Reimbursement and Market Access team, a well-recognized leader in developing and implementing innovative integrated market access strategies for drugs, biologics, devices and technologies across payers and settings. She has worked with the top global life sciences companies, a range of physician and non-physician provider groups as well as patient advocates.

Greg Gierer is the founder and Managing Principal for Hilltop Health Policy Advisors, a leading consulting practice that assists healthcare organizations in successfully navigating the legislative and regulatory health policy landscape.

Greg is a health policy expert with more than 20 years of experience in Washington, D.C., with demonstrated success in advocating before Congress, federal agencies, state governments, and policymakers. He has expertise in the federal legislative and regulatory policy process and success in achieving positive outcomes for healthcare organizations, including through the development and implementation of policy and advocacy strategies.

His areas of expertise include the Affordable Care Act; comprehensive healthcare reform; Medicare policy, including Medicare Advantage and Part D; prescription drug policy and drug pricing reforms; and health system and payment reforms.

Prior to launching Hilltop Health Policy Advisors, Greg served as Principal Consultant for Health Management Associates (HMA) as part of HMA’s Medicare and federal policy practice in Washington, D.C. 

Greg also served as Vice President of Policy and Research at the Better Medicare Alliance (BMA), the leading nonprofit research and advocacy organization focused on strengthening and improving the Medicare Advantage (MA) program. During his tenure at BMA, Greg led regulatory policy development and engagement with the Centers for Medicare & Medicaid Services (CMS) to advance BMA’s policy and advocacy priorities.

Prior to joining BMA, Greg was Senior Vice President for Policy at AHIP, where he led regulatory policy work and strategy related to the Affordable Care Act (ACA) implementation, including the successful implementation of the ACA exchanges and insurance market reform regulations. Later, Greg led policy-development work to advance public policies to strengthen and stabilize the exchange marketplace.

Previously, Greg held senior public policy roles at the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Blue Cross and Blue Shield Association. He started his career on Capitol Hill as a legislative aide to Senator Chris Dodd (D-CT).

Greg is also a skilled communicator and a nationally recognized thought-leader who has represented numerous healthcare organizations and associations at high-profile health policy and business conferences.

Greg earned his Master of Public Policy from Georgetown University and Bachelor of Arts from Providence College.

David Fox is a leading authority on the regulation of prescription and over-the-counter drugs, biological products, combination products, and controlled substances. Known for his collaborative approach to complex regulatory issues, David has successfully resolved numerous disputes between sponsors and staff at FDA on products that raise novel regulatory issues. As a former senior lawyer for FDA and throughout his career in private practice, David has been deeply immersed in the regulatory side of drug development, advising industry teams on gaining approval for novel products across numerous therapeutic classes, including respiratory, oncology, pain, addiction therapy, neurology and psychiatry, anti-infectives and anti-virals, vaccines and metabolic disorders. David is a graduate of the College of William and Mary (B.A. ’86) and NYU School of Law (J.D. ’89). He served as Assistant Chief of Enforcement and Associate Chief for Drugs in FDA’s Office of the Chief Counsel from 1994-2000.